Back

Effect of aspirin discontinuation according to individualised patient bleeding and ischemic risks after PCI: a TWILIGHT trial sub-analysis.

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Optimising PCI: imaging, pharmacology and more Complications ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Guiomar Mendieta Badimon

Hospital de la Santa Creu i Sant Pau, Barcelona (Spain)

3 More presentations in this session

Presentation thumbnail
Heparin pre-treatment in patients with ST elevation myocardial infarction: a cohort study investigating the effects on coronary artery occlusion, mortality, and bleeding
Mr O. Emilsson (Lund, SE)
Abstract Slides Video
Presentation thumbnail
Intravascular ultrasound-guided optimization for chronic total occlusion-percutaneous coronary intervention with multiple drug-eluting stents
Doctor S. Seo (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Shockwave intravascular lithotripsy (IVL) for calcified coronary lesions; a real world multicentre European study with long term follow up
Doctor W. Raja (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Optimising PCI: imaging, pharmacology and more

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
Abbreviated versus standard dual antiplatelet therapy time after PCI in high bleeding risk patients with acute coronary syndrome - a report from the SWEDEHEART registry
thumbnail
Congress Presentation
iRight4Me: individualisation of P2Y12 inihibitors in the realworld practice - an interim report

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources